Literature DB >> 27596361

Hypersomnolence-hyperkinetic movement disorder in a child with compound heterozygous mutation in 4-aminobutyrate aminotransferase (ABAT) gene.

Madhu Nagappa1, Parayil Sankaran Bindu2, Shwetha Chiplunkar3, Periasamy Govindaraj1, Gayathri Narayanappa4, Ayyappan Krishnan5, M M Srinivas Bharath6, Aarthi Swaminathan7, Jitender Saini7, Hanumanthapura R Arvinda7, Sanjib Sinha5, Pavagada S Mathuranath5, Arun B Taly1.   

Abstract

Deficiency of gamma-amino-butyrate aminotransferase (ABAT) is a rare inherited disorder. A six-month-old girl presented with hyper-somnolence, hyperkinetic movements of distal extremities during wakefulness, hypotonia, bi-pyramidal signs, and impaired response to sound and visual stimuli. Brain MRI at five months showed restricted diffusion along the internal capsule and genu of corpus callosum. A follow up MRI at 18months, showed hyperintensities in brainstem, external and internal capsule, 'trilaminated' appearance of posterior limb of internal capsule and dysmyelination of sub-cortical white matter. MRS showed a peak between 2.2ppm and 2.4ppm, corresponding to glutamine, glutamate and GABA. EEG was normal at six months but showed multifocal epileptiform discharges at 18months. Targeted exome sequencing revealed compound heterozygous missense variations in ABAT resulting in its reduced function. We report the novel association of hypersomnolence and hyperkinetic movement disorder with ABAT variations thus expanding the clinical spectrum of this uncommon neuro-metabolic disorder and discuss the emerging role of GABA in pathways regulating sleep-wake cycle and movement disorders.
Copyright © 2016 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ABAT; GABA; Hyperkinetic movement disorder; Hypersomnolence

Mesh:

Substances:

Year:  2016        PMID: 27596361     DOI: 10.1016/j.braindev.2016.08.005

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

Review 1.  Phenotype of GABA-transaminase deficiency.

Authors:  Mary Kay Koenig; Ryan Hodgeman; James J Riviello; Wendy Chung; Jennifer Bain; Claudia A Chiriboga; Kazushi Ichikawa; Hitoshi Osaka; Megumi Tsuji; K Michael Gibson; Penelope E Bonnen; Phillip L Pearl
Journal:  Neurology       Date:  2017-04-14       Impact factor: 9.910

2.  GABA Transaminase Deficiency With Survival Into Adulthood.

Authors:  Anaita U Hegde; Purva K Karnavat; R Vyas; Melissa L DiBacco; P Ellen Grant; Phillip L Pearl
Journal:  J Child Neurol       Date:  2019-01-15       Impact factor: 1.987

3.  2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.

Authors:  Adam D Kennedy; Kirk L Pappan; Taraka Donti; Mauricio R Delgado; Marwan Shinawi; Toni S Pearson; Seema R Lalani; William E Craigen; V Reid Sutton; Anne M Evans; Qin Sun; Lisa T Emrick; Sarah H Elsea
Journal:  Front Neurosci       Date:  2019-05-08       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.